

CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER

Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by a hydroxylalkylamino linker between the oligopeptide and vinblastine. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH). Also disclosed are novel cytotoxic agents that are derivatives of vinca alkaloid drugs.